A 42-year-old woman with stage IVB cervical carcinoma (metastatic to para-aortic lymph nodes and lung) is deemed unsuitable for concurrent chemoradiation. She has normal renal function and good performance status (ECOG 0). What is the drug of choice for first-line palliative chemotherapy?

Explanation

## First-Line Chemotherapy for Metastatic/Recurrent Cervical Cancer ### Standard Regimen for Advanced Disease **Key Point:** Cisplatin + Paclitaxel is the gold-standard first-line chemotherapy for metastatic or recurrent cervical carcinoma in patients with good performance status. ### Evidence Base The **GOG-204 trial** (phase III) compared four platinum-based doublet regimens in recurrent/metastatic cervical cancer: - Cisplatin + Paclitaxel - Cisplatin + Topotecan - Cisplatin + Gemcitabine - Carboplatin + Paclitaxel **Cisplatin + Paclitaxel emerged as the preferred regimen** with superior overall survival (12.3 months vs. 9.7–10.8 months for other arms) and acceptable toxicity profile. ### Dosing and Schedule | Component | Dose | Schedule | |-----------|------|----------| | **Cisplatin** | 75 mg/m² | Day 1, every 21 days | | **Paclitaxel** | 135 mg/m² | Day 1, every 21 days | | **Cycles** | 4–6 cycles | Until progression or toxicity | **High-Yield:** GOG-204 is the landmark trial that established cisplatin + paclitaxel as the standard first-line regimen for recurrent/metastatic cervical cancer. ### Why Cisplatin + Paclitaxel **Clinical Pearl:** This combination provides synergistic activity—cisplatin induces DNA crosslinks while paclitaxel stabilizes microtubules, preventing repair. The regimen has the best survival data among platinum doublets in cervical cancer. ### Comparison of Platinum-Based Doublets | Regimen | Median OS | Toxicity Profile | Evidence Level | |---------|-----------|------------------|----------------| | **Cisplatin + Paclitaxel** | 12.3 months | Moderate (neuropathy, nephrotoxicity) | Phase III (GOG-204) | | Cisplatin + Topotecan | 9.7 months | Hematologic toxicity | Phase III (GOG-204) | | Cisplatin + Gemcitabine | 10.8 months | Moderate | Phase III (GOG-204) | | Carboplatin + Paclitaxel | 10.6 months | Lower nephrotoxicity | Phase III (GOG-204) | ### When to Use Alternatives **Warning:** Carboplatin + Paclitaxel is reserved for patients with **contraindications to cisplatin** (severe renal impairment, significant hearing loss, or neuropathy). It has inferior survival compared to cisplatin-based regimens. **Tip:** Cisplatin + 5-FU is an older regimen with less favorable outcomes compared to cisplatin + paclitaxel and is not recommended as first-line therapy in the modern era. ### Supportive Care - Aggressive hydration and mesna for cisplatin nephrotoxicity - Antiemetics (5-HT3 antagonists + dexamethasone) - Premedication for paclitaxel hypersensitivity (dexamethasone, diphenhydramine, ranitidine) - Monitoring for peripheral neuropathy [cite:Harrison 21e Ch 107; Robbins 10e Ch 22]